Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-15
2011-03-15
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S867000
Reexamination Certificate
active
07906489
ABSTRACT:
The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specificallyC. difficileinfections.
REFERENCES:
patent: 3978211 (1976-08-01), Coronelli et al.
patent: 4918174 (1990-04-01), Mc Alpine et al.
patent: 5583115 (1996-12-01), McAlpine et al.
patent: 5767096 (1998-06-01), Hochlowski et al.
patent: 7378508 (2008-05-01), Chiu et al.
patent: 2006/0257981 (2006-11-01), Shue et al.
patent: 2007/0105791 (2007-05-01), Sears et al.
patent: 2007/0173462 (2007-07-01), Shue et al.
patent: 2007/0259949 (2007-11-01), Chiu et al.
patent: 2008/0194497 (2008-08-01), Chiu et al.
patent: 2009/0163428 (2009-06-01), Chiu et al.
patent: 2010/0009925 (2010-01-01), Shue et al.
patent: 2010/0010076 (2010-01-01), Chiu et al.
patent: 2010/0035833 (2010-02-01), Ichikawa et al.
patent: 2010/0081800 (2010-04-01), Chiu et al.
patent: WO 96/35702 (1996-11-01), None
patent: WO 2004/014295 (2004-02-01), None
patent: WO 2005/112990 (2005-12-01), None
patent: WO 2006/085838 (2006-08-01), None
Vippagunta, S.R., Brittain, H.G., Grant, D.J.W. (2001) Crystalline solids. Advanced Drug Delivery Reviews, vol. 48, pp. 3-26.
Morissette, S.L., Almarsson, Ö., Peterson, M.L., Remenar, J.F., Read, M.J., Lemmo, A.V., Ellis, S., Cima, M.J., Gardner, C.R. (2004) High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Advanced Drug Delivery Reviews, vol. 56, pp. 275-300.
Finegold, S.M., Molitoris, D., Vaisanen, M-L., Song, Y., Liu, c., Bolaños, M. (2004) In Vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria. Antimicrobial Agents and Chemotherapy, vol. 48, No. 12, p. 4898-4902.
Gerding, D.N., Johnson, S., Peterson, L.R., Mulligan, M.E., Silva, Jr., J. (1995) Clostridium Difficile-Associated Diarrhea and Colitis. Infection Control and Hosptial Epidemiology, vol. 16, No. 8, p. 459-477.
Ansel, H.C., Allen, Jr., L.V., Popovich, N.G. (1999) Pharmaceutical Dosage Forms and Drug Delivery Systems. Published by Lippincott Williams & Wilkins, p. 23-26, 179-180 and 196.
Credito et al, Antimicrobial Agents and Chemotherapy, Nov. 2004, p. 4430-4434 vol. 48, No. 11.
K.L. Credito, P.C. Appelbaum, “Antianaerobic Activity of OPT 80 Compared to Other Agents,” Hershey Medical Center Department of Pathology, (poster), 44th ICAAC (Oct. 30-Nov. 2, 2004) in Chicago.
Babakhani et al., “Narrow spectrum activity and low fecal protein binding of Opt-80 and its major hydrolysis metabolite (OP-1118)”, Program and Abstract of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, p. 212 (2007), XP008103008.
Gerber et al., “OPT-80, a macrocyclic antimicrobial agent for the treatment of clostridium difficile infections: a review”, Expert Opinion on Investigational Drugs, 17(4), p. 547-53 (2008), XP002479935.
Lewiston et al., “Determination of OPT-80 and its desisobutyryl metabolite (OP-1118) in human plasma by a LC/MS/MS method”, AAPS Journal , American Association of Pharmaceutical Scientists, (2005), XP008103043.
Okumu et al., “Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of clostridium difficile associated diarrhea (CDAD)”, Program and Abstract of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 204, (2004), XP008103005.
Shangle et al., “Safety and pharmacokinetics of OPT-80 in human volunteers”, Program and Abstract of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, p. 1 (2004), XP008103010.
Shue et al., “Safety, tolerance, and pharmacokinetics studies of OPT-80 in healthy volunteers following single and multiple oral doses”, Antimicrobial Agents and Chemotherapy, 52(4), p. 1391-1395 (2008), XP002517908.
Cambridge Crystallographic Data Centre Deposition No. 100349, (2000), CCDC No. 114782.
Chemical Abstracts registry entry 56645-60-4, Tiacumicin B, Copyright 2007, American Chemical Society, pp. 1-2.
Braga et al., “Making crystals from crystals: a green route to crystal engineering and polymorphism” Chemical Communications (2005) pp. 3635-3645.
Pharmaceutical Dosage Forms: Tablets, vol. 2, Published by Marcel Dekker, Inc., ed. by Lieberman, Lachman, and Schwartz, pp. 462-472, (1990).
Dean, J., Analytical Chemistry Handbook, Published by McGraw-Hill, Inc., pp. 10.23-10.26, (1995).
Jain et al., “Polymorphism in Pharmacy” Indian Drugs (1986) vol. 23, No. 6, pp. 315-329.
Swanson, R.N. et al., In Vitro and In Vivo Evaluation of Tiacumicins B and C againstClostridium difficile, Antimicrob. Agents Chemother., Jun. 1991, pp. 1108-1111.
Hochlowski, J.E. et al., Tiacumicins, A Novel Complex of 18-Membered Macrolides,J. Antibiotics, vol. XL, No. 5, pp. 575-588 (May 1987).
Arnone et al. “Structure Elucidation of the Macrocyclic Antibiotic Lipiarmycin” Journal of the Chemical Society, Perkin Transactions 1, Chemical Society, 1353-1359 (1987).
Caira “Crystalline Polymorphism of Organic Compounds” Topics in Current Chemistry 198:163-208 (1998).
Poduval et al. “Clostridium difficile and vancomycin-resistant enterococcus: the new nosocomial alliance” The American Journal of Gastroenterology 95(12):3513-3515 (2000).
Polymorphism in Pharmaceutical Solids, published 1999 by Marcel Dekker Inc, ed. By Harry G. Brittain, pp. 1-2.
The Condensed Chemical Dictionary, Tenth Edition, published 1981 by the Van Nostrand Reinhold Company, revised by Gessner G. Hawley, p. 35 and 835.
Theriault et al. “Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation . . . ” J Antibiot (Tokyo) 40(5):567-574 (1987).
Supplementary European Search Report issued in the corresponding European Patent Application No. 05712354.9 (Jan. 15, 2010).
Babakhani Farah
Chiu Yu-Hung
Hwang Chan-Kou
Okumu Franklin
Romero Alex
Goon Scarlett
Jiang Shaojia Anna
Morgan & Lewis & Bockius, LLP
Optimer Pharmaceuticals, Inc.
LandOfFree
18-membered macrocycles and analogs thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 18-membered macrocycles and analogs thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 18-membered macrocycles and analogs thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638752